Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer

N/AUnknownNCT05252065

Guizhou Medical University40 enrolled

Overview

Calculating which cardiac substructure accepting with the highest radiation dose by conventional radiotherapy, then to investigate the relationship between the changes of global longitudinal strain or cardiac magnetic resonance imaging and cardiac biomarkers and the certain cardiac substructure for stage N2-3 non-small cell lung cancer

All patients receive intensity-modulated radiotherapy (IMRT). The prescription dose of PTV is 60-70Gy，Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected before radiotherapy, at the end of radiotherapy (day 15), at the end of radiotherapy and at 1 month after radiotherapy. Echocardiography was performed before radiotherapy, in the middle of radiotherapy (day 15) and at the end of radiotherapy to obtain global longitudinal strain value. Cardiac magnetic resonance imaging is used to measure the blood flow of the anterior descending coronary artery before and at the end of radiotherapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non-small Cell Lung Cancer

Interventions

Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imagingOTHER

Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients at TNM stage N2-N3 NSCLC confirmed by histopathology or cytology using IASLC International TNM staging standard (8th edition) 2. KPS score \>80; Aged 18 to 75 year-old 3. No contraindications to radiotherapy 4. No history of heart disease before treatment 5. Patients receiving intensity modulated radiation therapy (IMRT) 6. Patients receiving PTV at a prescription dose of 60-70Gy by IMRT 7. Patients receiving radiotherapy alone and concurrent chemoradiotherapy Exclusion Criteria: 1. Patients with pleural effusion 2. Patients with serious medical illness or infection 3. Patients with acute myocardial infarction within 6 months 4. In patients with NYHA grade 3-4, baseline LVEF before radiotherapy is below 59% 5. Patients with congenital heart diseases, valvular diseases and arrhythmia 6. Patients with pericardial effusion 7. Patients receiving immunotherapy and drug targeted therapy 8. Patients with a history of anthracycline use

Outcomes

Primary Outcomes

Concentration of Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP

These levels are measured with the Siemens ADVIA Centaur XP Immunoassay System, normal ranges of Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are 0-0.03 ng/mL, 0-0.01 ng/mL, 0-0.04 ng/mL, 0-100 pg/mL, and 0-125pg/mL respectively

Time frame: through study completion, an average of 1 year

Global longitudinal strain value

global longitudinal strain value is obtained by offline analysis of 2-dimensional Echocardiography, reduction of more than 15% in left ventricular systole suggests some degree of cardiotoxicity by European Society of Cardiology 2016

Time frame: through study completion, an average of 1 year

The average flow velocity of the anterior descending coronary artery

obtained by phase contrast magnetic resonance arteriography of cardiac magnetic resonance imaging

Time frame: through study completion, an average of 1 year

Central Contacts

Yiying Zhu

CONTACT

+8515989775891 347454648@qq.com

Bing Lu

CONTACT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.